Pharmacokinetics and Safety of Topical Administration of Brimonidine Tartrate Ophthalmic Solution 0.025%.
- First Posted Date
- 2014-01-20
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 12
- Registration Number
- NCT02039765
- Locations
- 🇺🇸
Bausch & Lomb, Incorporated, Rochester, New York, United States
Loteprednol Ophthalmic Gel for the Treatment of Ocular Inflammation and Pain Following Cataract Surgery
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2020-09-25
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 514
- Registration Number
- NCT01996839
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Bridgewater, New Jersey, United States
Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 507
- Registration Number
- NCT01959243
- Locations
- 🇺🇸
Bausch Site 3, Phoenix, Arizona, United States
🇺🇸Bausch Site 2, Philadelphia, Pennsylvania, United States
🇺🇸Bausch Site 1, Andover, Massachusetts, United States
A Study to Evaluate a Mid Add Multi-Focal Soft Contact Lens
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2020-09-30
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 146
- Registration Number
- NCT01959178
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Rochester, New York, United States
Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 60
- Registration Number
- NCT01959230
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Memphis, Tennessee, United States
Long-Term Safety of Latanoprostene Bunod Ophthalmic Solution 0.024% in Japanese Subjects With OAG or OHT
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 130
- Registration Number
- NCT01895972
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Bridgewater, New Jersey, United States
Efficacy of Latanoprostene Bunod in Lowering Intraocular Pressure in Japanese Healthy Male Volunteers
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2018-05-15
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT01895985
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Madison, New Jersey, United States
A Study to Evaluate the Product Performance of a New Silicone Hydrogel Contact Lens
- First Posted Date
- 2013-06-10
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 400
- Registration Number
- NCT01873846
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Madison, New Jersey, United States
Hydrophobic Acrylic Toric IOL Designed to Reduce the Effects of Preoperative Corneal Astigmatism
Not Applicable
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2020-09-16
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 191
- Registration Number
- NCT01852084
- Locations
- 🇺🇸
Bausch & Lomb, Irvine, California, United States
Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-03-25
- Last Posted Date
- 2019-08-30
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 102
- Registration Number
- NCT01817582
- Locations
- 🇺🇸
Bausch & Lomb Incorporated, Irvine, California, United States
© Copyright 2024. All Rights Reserved by MedPath